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Schizophrenia is a severe mental illness that constitutes a prototype of psychiatric disorders, although its aetiopathogenic basis is not entirely known. According to epidemiological studies, its prevalence fluctuates between 0.5% and 1.0% in the population. (1) The World Health Organization classifies this illness as among the top ten disorders causing a greater disability in the adult population. (2) During the last 60 years and following the introduction of chlorpromazine into clinical practice, the mainstay treatment of schizophrenia has been based on the use of antipsychotic drugs. (3) The first drugs, termed 'first-generation drugs' (i.e.
classical or typical drugs), showed great efficacy in reducing positive symptoms (e.g. hallucinations and delusions); however, a main limitation of these drugs was the onset of extrapyramidal side effects (EPS). The reintroduction of clozapine in the United
States -a neuroleptic commercialised in the 1960s that was later withdrawn due to its ability to induce agranulocytosis (4) brought a dramatic change in research expectations. This agent, apart from causing few EPS, showed clinical efficacy in improving both positive and negative symptoms in patients who were refractory to other first-generation antipsychotic drugs. (5) The reintroduction of clozapine, together with the introduction of risperidone in 1993, (4) opened the door to 'atypical antipsychotics', (6) also known as second-generation antipsychotic drugs (SGAs).
The advances achieved in the field of antipsychotic drugs in the past 30 years have been incredibly important, leading to the clinical introduction of numerous SGAs (Table I) .
These agents have notably improved the quality of life of psychotic patients and contributed toward reducing the stigma associated with such a crippling disease. increase. (8) We hypothesised that this increase in research would have correlated with an increase in the volume of published scientific literature on these drugs and thus proceeded to analyse published scientific literature on SGAs in Singapore.
A bibliometric study of scientific research conducted on second-generation antipsychotic drugs in Singapore
Although Singapore is an emergent country with a highly developed, market-based economy, it has a short psychiatric history. A substantial proportion of people in Singapore rely on a mixture of Western and traditional medicines, and seek help from spiritual healers or practitioners of traditional medicine; in some instances, this results in delayed psychiatric treatment. (9) There are about 115 practising psychiatrists in Singapore, giving a psychiatrist-to-population ratio of 2.6/100,000, which is low compared to other developed countries such as the United
States of America (USA), which has a psychiatrist-to-population ratio of 13.7/100,000. (10) However, the Ministry of Health in Singapore has supported the local development of the field of psychiatry and the use of evidence-based practice guidelines; it has also published clinical practice guidelines on schizophrenia (10) and bipolar disorder (11) to provide doctors and patients in Singapore with evidence-based guidance on the management of these disorders.
Bibliometric studies are useful tools for assessing the social and scientific relevance of a given discipline or field, and may be of particular interest to different health professionals such as policy makers, researchers and clinicians. (12) In recent years, our group has, using a bibliometric approach, studied the evolution of scientific literature in psychiatry pertaining to the different aspects of different psychiatric disorders and the specific therapeutic modalities being pursued within the field of psychopharmacology. (8, (13) (14) (15) (16) (17) In the present study, we had the specific aim of conducting a bibliometric assessment of the scientific literature published on SGAs in Singapore from 1997 to 2011. There has only been a slight increase in the number of publications on SGAs generated in Singapore over the last 15 years (Fig. 1) . Mathematical adjustments to the exponential and linear curves confirmed that the increase in the literature for both SGAs and total antipsychotic drugs did not conform to the postulates of Price's Law, possibly due to the small sample of publications (Fig. 2) . The relative five-year growth of publications on SGAs and total antipsychotics in Singapore during the period studied, with the 2007-2011 interval taken as reference, is shown in Fig. 3 . The cumulative growth in the literature was lower than the overall global growth of scientific output in the field of biomedicine and health sciences, and slightly less in the specific field of psychiatry and neurology
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within Singapore. of all articles retrieved on our searches (Table III) , and the journals most extensively used for the dissemination of research on SGAs had reasonably high IFs, with four journals having IF > 2.
On manual classification, 37.26% of the articles retrieved were found to belong to the clinical efficacy group, 31.37% to the tolerance and/or safety group, 19.62% to the experimental pharmacology group and 11.65% to the not specified group The general publication output on SGAs from Singapore (PI = 0.32) was low when compared to the worldwide publication output during the period analysed. Table IV shows how Singapore compares with the top ten most productive countries in the fields of biomedicine and health sciences, and psychiatry and neurology. USA (PI = 31.63), followed by the United Kingdom (UK), Germany, Canada, Italy and Spain were the six most productive countries in terms of publication output on SGAs. However, when the productivity of these countries on SGAs was assessed in relation to their overall productivity in the field of psychiatry and neurology, only Spain was found to have a higher percentage of research on SGAs (Fig. 4) . Singapore has been recommended for treating treatment-resistant major depressive disorders. In addition, aripiprazole was approved in 2007 by FDA as an add-on to antidepressants for the treatment of treatment-resistant major depression. (25) SGAs are also commonly used, and studied, in numerous off-label indications for conditions such as substance-induced psychosis, agitation symptoms, tics and substance-abuse disorders. (26, 27) Another aspect of interest in relation to scientific production that we analysed in the present study, is the quality of the publications. The fact that prestigious journals such as the Notably, four among the six journals in which research was most widely cited had a significant impact in the field of psychiatry (IF > 2).
As we have shown in earlier studies, (16, 17) 
With regard to the PI of the different countries in the production of scientific literature on SGAs, USA and UK, two major English-speaking countries, head the ranking; these two countries generate over a third of the total scientific publication in the field (38.55%). The fact that these two countries are home to many of the major pharmaceutical companies responsible for the development of SGAs (e.g. Eli
Lilly -olanzapine; Janssen Pharmaceutica -risperidone and paliperidone; AstraZeneca -quetiapine; Pfizer -ziprasidone;
Bristol-Myers Squibb/Otsuka Pharmaceutical -aripiprazole) may explain these countries' high PIs. In the other countries that appear near the top in the ranking for production of scientific literature on SGAs with respect to general productivity in the field of psychiatry and neurology (e.g. Spain, Italy and Canada), (20) except for U SA and Japan (data from O EC D 20 0 9), (20) China (data from O EC D 20 07), (20) and 
The correlation of the production of scientific literature on SGAs with the per capita health expenditure of each country offered a different perspective to our findings. In general, there was confirmation of the perception that the higher the spending on health, the greater a country's research production. as predicting how such trends might evolve over time.
In conclusion, the present study provides a glimpse into the evolution of research on SGAs in Singapore vis-à-vis the parameters of quality and dissemination that are most commonly used at an international level. SGAs formed the top drug class in terms of market share (USD 14.6 billion per year)
in the year 2008 in USA. (25) Given the ever-growing importance of this class of drugs, the fact that an ideal antipsychotic drug has yet to be found, (7) and the fact that the exact aetiopathogenesis of schizophrenia remains to be revealed, we are of the opinion that research on SGAs will continue to grow in the coming years.
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